FDA Clears Cepheid's Xpert CT/NG Test | GenomeWeb

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared Cepheid's Xpert CT/NG test for marketing, the Sunnyvale, Calif.-based company announced after the close of the market on Thursday.

The test for the rapid detection and differentiation of chlamydia and Neisseria gonorrhoeae runs on Cepheid's GeneXpert system and allows for the same-day patient consultation and treatment of the two most common sexually transmitted bacterial infections in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.